Gabapentin News and Research

RSS
Gabapentin (brand name Neurontin) is a medication originally developed for the treatment of epilepsy. Presently, gabapentin is widely used to relieve pain, especially neuropathic pain.
Depomed third quarter 2012 revenue increases to $33.3 million

Depomed third quarter 2012 revenue increases to $33.3 million

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

Favorable preliminary results from XenoPort’s XP23829 Phase 1 trial on RRMS, psoriasis

Limited positive effect of Tafamidis in neurological disorders

Limited positive effect of Tafamidis in neurological disorders

Unique approaches to improve pain management in hospitals and clinical practices

Unique approaches to improve pain management in hospitals and clinical practices

Chronic nerve pain: an interview with Professor Sally Lawson

Chronic nerve pain: an interview with Professor Sally Lawson

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

XenoPort initiates XP23829 Phase 1 study in healthy adults

XenoPort initiates XP23829 Phase 1 study in healthy adults

Once-daily Gralise significantly reduces pain intensity in PHN patients

Once-daily Gralise significantly reduces pain intensity in PHN patients

Regnite to treat primary restless legs syndrome launched in Japan

Regnite to treat primary restless legs syndrome launched in Japan

Depomed acquires all rights to Zipsor from Xanodyne

Depomed acquires all rights to Zipsor from Xanodyne

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

UCSF scientists aim to use embryonic stem cells for treatment of neuropathic pain

UCSF scientists aim to use embryonic stem cells for treatment of neuropathic pain

XenoPort first quarter revenues increase to $10.4 million

XenoPort first quarter revenues increase to $10.4 million

Latest AAN/AHS guidelines can help prevent migraine attacks

Latest AAN/AHS guidelines can help prevent migraine attacks

Botox effect modest in migraine prevention: Study

Botox effect modest in migraine prevention: Study

Gabapentin drug helps people to quit cannabis

Gabapentin drug helps people to quit cannabis

Migraine prevention guidelines released

Migraine prevention guidelines released

Impax initiates challenge of patents related to generic Gralise

Impax initiates challenge of patents related to generic Gralise

Positive effect of tafamidis on neurological degeneration

Positive effect of tafamidis on neurological degeneration